26 July 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Anti-cancer Research
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
We are delighted to share some highly cited papers on anti-cancer research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
“Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives”
by Robert Jenke, Nina Reßing, Finn K. Hansen, Achim Aigner and Thomas Büch
Cancers 2021, 13(4), 634; https://doi.org/10.3390/cancers13040634
Available online: https://www.mdpi.com/2072-6694/13/4/634
“3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs”
by Mélanie A. G. Barbosa, Cristina P. R. Xavier, Rúben F. Pereira, Vilma Petrikaitė and M. Helena Vasconcelos
Cancers 2022, 14(1), 190; https://doi.org/10.3390/cancers14010190
Available online: https://www.mdpi.com/2072-6694/14/1/190
“Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin”
by Esra Küpeli Akkol, Iffet Irem Tatlı, Gökçe Şeker Karatoprak, Osman Tuncay Ağar, Çiğdem Yücel, Eduardo Sobarzo-Sánchez and Raffaele Capasso
Cancers 2021, 13(11), 2733; https://doi.org/10.3390/cancers13112733
Available online: https://www.mdpi.com/2072-6694/13/11/2733
“Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update”
by Jen-Fu Hsu, Shih-Ming Chu, Chen-Chu Liao, Chao-Jan Wang, Yi-Shan Wang, Mei-Yin Lai, Hsiao-Chin Wang, Hsuan-Rong Huang and Ming-Horng Tsai
Cancers 2021, 13(2), 195; https://doi.org/10.3390/cancers13020195
Available online: https://www.mdpi.com/2072-6694/13/2/195
“Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review”
by Sareh Kamran, Ajantha Sinniah, Mahfoudh A. M. Abdulghani and Mohammed Abdullah Alshawsh
Cancers 2022, 14(5), 1100; https://doi.org/10.3390/cancers14051100
Available online: https://www.mdpi.com/2072-6694/14/5/1100
“The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions”
by Tadeusz Robak, Magda Witkowska and Piotr Smolewski
Cancers 2022, 14(3), 771; https://doi.org/10.3390/cancers14030771
Available online: https://www.mdpi.com/2072-6694/14/3/771
“The Renaissance of Cyclin Dependent Kinase Inhibitors”
by Tobias Ettl, Daniela Schulz and Richard Josef Bauer
Cancers 2022, 14(2), 293; https://doi.org/10.3390/cancers14020293
Available online: https://www.mdpi.com/2072-6694/14/2/293
“Cancer Cell Metabolism and Drug Targets” Edited by: Dr. Daniel S. Sitar and Prof. Dr. Donald Miller |
“Drug Resistance in Gastrointestinal Cancer” Edited by: Dr. Rosalba D’Alessandro and Dr. Carmelo Ferrai
|
“Anticancer Drugs: Recent Advances and Challenges” Edited by: Dr. Moutih Rafei and Dr. Sebastien Talbot |
“Drug Development for Acute Lymphoblastic Leukemia” Edited by: Dr. Rajesh Ramakrishnan Nair |
We hope this announcement will provide useful information for this field.